Form 4: Ultragenyx Pharmaceutical Inc. Executive Sells Shares

A senior executive at Ultragenyx Pharmaceutical Inc. has sold a portion of their common stock holdings.

Summary

• Theodore Alan Huizenga, a Senior Vice President and Chief Accounting Officer at Ultragenyx Pharmaceutical Inc., has sold 648 shares of common stock.
• The transaction occurred on December 10, 2024.
• The sale included shares previously reported as underlying Restricted Stock Units (RSUs) that are subject to vesting conditions.
• Additionally, 237 shares were acquired through the company's 2014 Employee Stock Purchase Plan on October 31, 2024.

Sentiment

Score: 5

Explanation: The document is a routine disclosure of an executive stock sale, which is neither positive nor negative in itself. The sentiment is neutral.

Industry Context

Executive stock sales are a common occurrence in publicly traded companies and are often scrutinized by investors for insights into management's perspective on the company's future.

Comparison to Industry Standards

• Executive stock sales are a normal part of compensation and portfolio management for executives in publicly traded companies.
• The number of shares sold is relatively small compared to the total outstanding shares of Ultragenyx, and is not unusual for an executive at this level.

Stakeholder Impact

• The stock sale may have a minor impact on the stock price, but is unlikely to have a significant effect on the company's operations or long-term prospects.

Key Dates

Keywords

Ultragenyx, stock sale, executive, common stock, RSU, employee stock purchase plan, insider trading